Sanofi

News

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo

News

Sanofi says new drugs can add €10bn to sales by 2030

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of th

News

Merck pummelled as MS hope evobrutinib dies in phase 3

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th

News

Sanofi expands GenAI drug discovery pact with Aqemia

Sanofi has deepened an existing collaboration with artificial intelligence specialist Aqemia in the latest among a flurry of collaborations between pharma companies and ge

News

Dupixent aces second COPD study, setting up FDA filing

With a second positive phase 3 trial in hand, Sanofi and Regeneron have said they plan to file for approval of Dupixent in chronic obstructive pulmonary disease (COPD), a

Patients

‘What If?’ Poetry as a platform for the patient voice

Patient centricity has been a key focus for pharma in 2023. However, extending beyond the merely discursive topic into sustained and tangible action at scale has been somewhat limited.

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Sanofi says new drugs can add €10bn to sales by 2030

Merck pummelled as MS hope evobrutinib dies in phase 3

Sanofi expands GenAI drug discovery pact with Aqemia

Dupixent aces second COPD study, setting up FDA filing

‘What If?’ Poetry as a platform for the patient voice

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Sanofi

Editor's Picks